| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2000 | Mechanism of action of camptothecin | Liu L.F.; Desai S.D.; TSAI-KUN LI ; Mao Y.; Sun M.; Sim S.-P. | Annals of the New York Academy of Sciences | | 358 | |
| 2017 | MicroRNA-183 Mediates Protective Postconditioning of the Liver by Repressing Apaf-1 | Lin H.-C.; Liu S.-Y.; Yen E.-Y.; TSAI-KUN LI ; Lai I.-R. | Antioxidants and Redox Signaling | 9 | 8 | |
| 2011 | Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway | Toh Y.-M.; TSAI-KUN LI | Clinical Cancer Research | 21 | 20 | |
| 1998 | Modulation of gyrase-mediated DNA cleavage and cell killing by ATP | TSAI-KUN LI ; Liu L.F. | Antimicrobial Agents and Chemotherapy | | 17 | |
| 2012 | Multiple domains of the Tobacco mosaic virus p126 protein can independently suppress local and systemic RNA silencing | Wang L.-Y.; Lin S.-S.; Hung T.-H.; TSAI-KUN LI ; Lin N.-C.; Shen T.-L. | Molecular Plant-Microbe Interactions | 39 | 37 | |
| 2013 | A negative feedback of the HIF-1α pathway via interferon-stimulated gene 15 and ISGylation | Yeh Y.-H.; Yang Y.-C.; Hsieh M.-Y.; Yeh Y.-C.; TSAI-KUN LI | Clinical Cancer Research | 23 | 21 | |
| 2003 | Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)2,3-methylenedioxy-5H-dibenzo[c,h][1,6] naphthyridin-6-ones: Effect on topoisomerase-I targeting activity and cytotoxicity | Singh S.K.; Ruchelman A.L.; TSAI-KUN LI ; Liu A.; Liu L.F.; LaVoie E.J. | Journal of Medicinal Chemistry | 47 | 43 | |
| 2004 | Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N, N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: Influence on topoisomerase I-targeting activity and cytotoxicity | Ruchelman A.L.; Kerrigan J.E.; TSAI-KUN LI ; Zhou N.; Liu A.; Liu L.F.; LaVoie E.J. | Bioorganic and Medicinal Chemistry | 28 | 28 | |
| 2014 | A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase i | Yu C.-C.; Pan S.-L.; Chao S.-W.; Liu S.-P.; Hsu J.-L.; Yang Y.-C.; TSAI-KUN LI ; Huang W.-J.; Guh J.-H. | Biochemical Pharmacology | 23 | 22 | |
| 2013 | On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs | Wu C.-C.; Li Y.-C.; Wang Y.-R.; TSAI-KUN LI ; Chan N.-L. | Nucleic Acids Research | 111 | 109 | |
| 2019 | The paracrine induction of prostate cancer progression by caveolin-1 | Lin C.-J.; Yun E.-J.; Lo U.-G.; Tai Y.-L.; Deng S.; Hernandez E.; Dang A.; Chen Y.-A.; Saha D.; Mu P.; Lin H.; TSAI-KUN LI ; Shen T.-L.; Lai C.-H.; Hsieh J.-T. | Cell Death and Disease | 20 | 20 | |
| 2007 | Prazosin displays anticancer activity against human prostate cancers: Targeting DNA and cell cycle | Lin S.-C.; Chueh S.-C.; Hsiao C.-J.; TSAI-KUN LI ; Chen T.-H.; Liao C.-H.; Lyu P.-C.; Guh J.-H. | Neoplasia | 55 | 55 | |
| 2017 | Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry | Wang Y.-R.; Chen S.-F.; Wu C.-C.; Liao Y.-W.; Lin T.-S.; Liu K.-T.; Chen Y.-S.; TSAI-KUN LI ; Chien T.-C.; Chan N.-L. | Nucleic Acids Research | 42 | 38 | |
| 2012 | QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells | Chen M.-C.; Pan S.-L.; Shi Q.; Xiao Z.; Lee K.-H.; TSAI-KUN LI ; Teng C.-M. | Cancer Science | 12 | 12 | |
| 2018 | Regioselective synthesis and biological evaluation of: N -substituted 2-aminoquinazolin-4-ones | Liao Z.-Y.; Yeh W.-H.; Liao P.-Y.; Liu Y.-T.; Chen Y.-C.; Chen Y.-H.; Hsieh T.-H.; Lin C.-C.; Lu M.-H.; Chen Y.-S.; Hsu M.-C.; TSAI-KUN LI ; Chien T.-C. | Organic and Biomolecular Chemistry | 9 | 9 | |
| 2020 | Retraction notice to “Design, synthesis, and biological evaluation of heterotetracyclic quinolinone derivatives as anticancer agents targeting topoisomerases” [Eur. J. Med. Chem. 190 (2020) 112074] (European Journal of Medicinal Chemistry (2020) 190 (S0223523420300416), (10.1016/j.ejmech.2020.112074)) | Lee J.-F.; Chang T.-Y.; Liu Z.-F.; Lee N.-Z.; Yeh Y.-H.; Chen Y.-S.; Chen T.-C.; Chou H.-S.; TSAI-KUN LI ; Lee S.-B.; Lin M.-H. | European Journal of Medicinal Chemistry | 0 | 0 | |
| 2016 | Rhapontigenin inhibits TGF-β-mediated epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway and is not associated with HIF-1α degradation | Yeh Y.-H.; Wang S.-W.; Yeh Y.-C.; Hsiao H.-F.; TSAI-KUN LI | Oncology Reports | 17 | 19 | |
| 2020 | The role of extracellular vesicles in prostate cancer with clinical applications | Tai Y.-L.; Lin C.-J.; TSAI-KUN LI ; Shen T.-L.; Hsieh J.-T.; Chen B.P.C. | Endocrine-Related Cancer | 7 | 5 | |
| 2012 | Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway | Hsu J.-L.; Ho Y.-F.; TSAI-KUN LI ; Chen C.-S.; Hsu L.-C.; Guh J.-H. | Biochemical Pharmacology | 18 | 15 | |
| 2020 | Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase–negative cells | Zencir S.; Hsieh M.-H.; Hsu J.-S.; Ergun Y.; Chou G.-L.; TSAI-KUN LI ; Teng S.-C.; Topcu Z. | Journal of Cancer Research and Clinical Oncology | 3 | 3 | |
